Clarus Therapeutics Holdings (CRXT) Income Statement
0 Followers
Clarus Therapeutics Holdings Income Statement
Last quarter (Q ), Clarus Therapeutics Holdings's total revenue was $4.05M, an increase of 0.97% from previous quarter. In Q, Clarus Therapeutics Holdings's net income was $-10.69M. See Clarus Therapeutics Holdings’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 21
Total Revenue
$ 13.96M
Cost of Revenue
$ 2.72M
Gross Profit
$ 11.24M
Operating Expense
$ 50.97M
Operating Income
$ -39.73M
Net Non Operating Interest Income Expense
$ -15.89M
Other Income Expense
$ 15.01M
Pretax Income
$ -40.62M
Tax Provision
$ 0.00
Earnings From Equity Interest Net Of Tax
-
Net Income Common Stockholders
$ -40.20M
Basic EPS
$ -5.72
Diluted EPS
$ -5.72
Basic Average Shares
$ 7.03M
Diluted Average Shares
$ 7.03M
Dividend Per Share
-
Total Operating Income As Reported
-
Reported Normalized Basic E P S
-
Reported Normalized Diluted E P S
-
Rent Expense Supplemental
-
Total Expenses
$ 53.69M
Net Income From Continuing And Discontinued Operation
$ -40.62M
Normalized Income
$ -55.63M
Interest Expense
$ 15.89M
EBIT
$ -24.72M
EBITDA
$ -24.70M
Currency in USD
Clarus Therapeutics Holdings Earnings and Revenue History